Qingjin Yiqi Granules for patients in pneumonia recovery phase (COVID-19, Omicron): a clinical study

Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine0 个研究点开始时间: 待定最近更新: 2023年2月20日

试验速览

暂无简介。

•1) Patients who meet the diagnostic and discharge criteria for COVID-19, and who have been negative for 2019-nCoV nucleic acid test after discharge.
•2) Pediatric patients are less than or equal to 14 years; adult patients are older than 14years.
•3) Patient informed consent.

•1) Patients who have undergone operations that affect lung function, such as lung transplantation, lung resection, lung volume reduction, etc;
•2) Patients who rely on mechanical ventilation to maintain lung function, such as ventilators;
•3) Combined with chronic lung diseases that affect lung function, such as severe chronic obstructive pulmonary disease;
•4) Patients complicated with diseases affecting cardiac function, such as patients with heart failure and pacemakers, etc;
•5) Accompanied by severe underlying diseases, such as uncontrolled heart, kidney, digestive, hematologic, neuropsychiatric, immune, metabolic diseases of clinical significance, malignant tumor, and severe malnutrition, etc;
•6) Resting heart rate > 120/min;
•7) Systolic blood pressure > 180mmhg or diastolic blood pressure > 100mmhg;
•8) Patients with unstable angina pectoris or myocardial infarction within the last one month;
•9) Severe obesity (BMI > 30kg/m2);
•10) Allergic constitution, allergic to the drug components involved in the treatment program;
•11) Pregnant or lactating women;
•12) patients who are participating in other clinical trials;
•13) patients with enrollment complexity or poor compliance, which will affect the evaluation of effect and safety.

发起方

Second Affiliated Hospital of Tianjin University of Traditional Chinese Medicine